ClinVar Miner

Submissions for variant NM_000256.3(MYBPC3):c.1351+2T>C (rs397515897)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000158072 SCV000208007 pathogenic not provided 2017-08-10 criteria provided, single submitter clinical testing The c.1351+2 T>C variant in the MYBPC3 gene has been published previously in association with HCM (Alfares et al., 2015). This variant destroys the canonical splice donor site in intron 15 and is predicted to cause abnormal gene splicing. Other splice site variants in the MYBPC3 gene have been reported in the Human Gene Mutation Database in association with cardiomyopathy (Stenson et al., 2014). Furthermore, the c.1351+2 T>C variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server).
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology RCV000656564 SCV000778610 pathogenic Familial hypertrophic cardiomyopathy 4 2018-05-08 criteria provided, single submitter research
Invitae RCV000815508 SCV000955966 likely pathogenic Hypertrophic cardiomyopathy 2018-12-07 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 15 of the MYBPC3 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individuals affected with hypertrophic cardiomyopathy (PMID: 25611685, 27532257, Invitae). ClinVar contains an entry for this variant (Variation ID: 42525). Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000815508 SCV000059039 pathogenic Hypertrophic cardiomyopathy 2011-03-10 criteria provided, single submitter clinical testing The 1351+2T>C variant has not been reported in the literature. However, it is pr edicted to cause abnormal splicing because the nucleotide substitution occurs in the highly conserved splice consensus sequence. Loss of function of the MYBPC3 gene is an established disease mechanism in HCM patients and splice site variant s can lead to loss of function by generating less or completely absent protein. Therefore, this variant is highly likely to be causative of HCM.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.